Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

Darren Pan, Eric Chinaeke, Yi-Hsuan Liu, Oluwabunmi Emidio, Caleb Paydar, Angele Kotomale, Monica Ahlquist, Bruce Feinberg, Agne Paner-Straseviciute, Jessica Fowler, Xinke Zhang

Blood (2025) 146 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2025-2818

Published: 2025

Journal Articles

Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA

Blood (2025) 146 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2025-2751

Published: 2025

Journal Articles

Real-world disease burden and treatment patterns among triple-class–exposed patients with relapsed/refractory multiple myeloma and extramedullary disease in the US: A retrospective analysis using Flatiron Health electronic medical records

Noa Biran, Jennifer S. Harper, Elissa E. Min, Yi-Hsuan Liu, Niodita Gupta-Werner, Jessica Fowler, Xinke Zhang, Hans Lee

Blood (2025) 146 (Supplement 1): 4582.

https://doi.org/10.1182/blood-2025-4582

Published: 2025

Journal Articles

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Jay Hydren, Rachel Jensen, Jorge Arturo Hurtado Martinez, Jennifer Ahlstrom, Mason Barnes, Caitlin Costello, Gurbakhash Kaur, Meera Mohan, Francesca Cottini, Douglas Sborov, Shaji Kumar, Noopur Raje, Philippe Moreau, Maithili Deshpande, Niodita Gupta-Werner, Tonya Le Blanc, Jessica Fowler, Rahul Banerjee

Blood (2025) 146 (Supplement 1): 6354.

https://doi.org/10.1182/blood-2025-6354

Published: 2025

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Yair Levy, Nina Kim, Siraje Mahmud, Bingcao Wu, Laura Ensley, Dee Lin, Monica Lisi, Felice Yang, Lorraine Brisbin, Jessica Fowler, Laura Hester, Agne Paner-Straseviciute, Sian Walker, Christina Hearty, R. Steven Paulson

Blood (2024) 144 (Supplement 1): 7851.

https://doi.org/10.1182/blood-2024-210497

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Rahul Banerjee, Nina Kim, Monal Kohli, Emeka Umeh, Dee Lin, Gideon Aweh, Jessica Fowler, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Bingcao Wu

Blood (2024) 144 (Supplement 1): 3792.7.

https://doi.org/10.1182/blood-2024-210750

Published: 2024

Journal Articles

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Aimaz Afrough, Adeel M Khan, Eric Chinaeke, Nina Kim, Jinghua He, Elissa E. Min, Bingcao Wu, Dee Lin, Agne Paner-Straseviciute, Laura Hester, Jessica Fowler, Sian Walker, Christina Hearty, Larry D Anderson, Jr.

Blood (2024) 144 (Supplement 1): 933.

https://doi.org/10.1182/blood-2024-209008

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7843.

https://doi.org/10.1182/blood-2024-208708

Published: 2024

Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Robert Rifkin, Henning Schade, Gary Simmons, Christopher Yasenchak, Jessica Fowler, Thomas S. Lin, Lijuan Kang, Weiming Xu

Blood (2024) 144 (Supplement 1): 4753.

https://doi.org/10.1182/blood-2024-207295

Published: 2024

Journal Articles

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Carlyn Rose Tan, Nina Kim, Eric Chinaeke, Laura Hester, Jessica Fowler, Dina Gifkins, Dee Lin, Sian Walker, Alex Z. Fu, Bingcao Wu

Blood (2023) 142 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2023-178896

Published: 2023

Journal Articles

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Ediz S. Calay, Yi Lin, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Eli Silvert, Nina Kim, Corinne Carpenter, Tyler E. Wagner, Jessica Fowler, Laura Hester, Alexander Marshall, Patrick Stoy, Dina Gifkins, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2023-174270

Published: 2023

Journal Articles

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Rahul Banerjee, Nina Kim, Monal Kohli, Laura Hester, Emily Achter, Jessica Fowler, Emeka Umeh, Dee Lin, Gideon Aweh, Dina Gifkins, Sian Walker, Bingcao Wu

Blood (2023) 142 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2023-178908

Published: 2023

Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Robert M. Rifkin, Jeff P. Sharman, Jessica Fowler, Thomas S. Lin, Brian Thomson, Jesus G. Berdeja

Blood (2023) 142 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2023-185257

Published: 2023

Journal Articles

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Ben A Derman, Meaghan Roach, Dee Lin, Bingcao Wu, Richard Murphy, Nina Kim, Margaret Doyle, Nadya Prood, Jessica Fowler, Alexander Marshall, Amal Jamaleddine, Agne Paner-Straseviciute

Blood (2023) 142 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2023-187479

Published: 2023

Journal Articles

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Daanish Hoda, Edward Faber, Jr., Bradley Hunter, Abhinav Deol, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C. Jackson, Jessica Fowler, Ariel Berger, Andrea L Lorden, Raj Stewart

Blood (2021) 138 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2021-145943

Published: 2021

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Katja Weisel, MD, George F. Geils, MD, Lionel Karlin, MD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Tae-Hoon Chung, Chang-Ki Min, MD PhD, Kazutaka Sunami, MD PhD, Amanda Goldrick, MD, Belle Fang, Jessica Fowler, PhD, Maria-Victoria Mateos, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133908

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA

Real-world disease burden and treatment patterns among triple-class–exposed patients with relapsed/refractory multiple myeloma and extramedullary disease in the US: A retrospective analysis using Flatiron Health electronic medical records

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only